






1-14-05

1FW 1642

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. <b>270/070 (UMD-0070)</b>	
Applicant(s): <b>John Langenfeld</b>					
Application No. <b>10/044,716</b>	Filing Date <b>January 11, 2002</b>	Examiner <b>Stephen L. Rawlings</b>	Customer No. <b>46046</b>	Group Art Unit <b>1642</b>	Confirmation No. <b>1276</b>
Invention: <b>BONE MORPHOGENETIC PROTEIN-2 IN THE TREATMENT AND DIAGNOSIS OF CANCER</b>					
 <b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	56 -	64 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	6 -	6 =	0	x \$88.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>50-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ Signature			Dated: <b>January 13, 2005</b>		
<b>Jane Massey Licata</b> <b>Reg. No. 32,257</b> <b>Licata &amp; Tyrrell P.C.</b> <b>66 E. Main Street</b> <b>Marlton, NJ 08053</b> <b>Tel: 856-810-1515</b> <b>Fax: 856-810-1454</b>			<div style="border: 1px solid black; padding: 5px;">           I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____            (Date)         </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">           _____            Signature of Person Mailing Correspondence         </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">           _____            Typed or Printed Name of Person Mailing Correspondence         </div>		
CC:					

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b>			Docket No. 270/070 (UMD-0070)	
Applicant(s): John Langenfeld				
Application No. 10/044,716	Filing Date January 11, 2002	Examiner Stephen L. Rawlings	Customer No. 46046	Group Art Unit 1642
Invention: <b>BONE MORPHOGENETIC PROTEIN-2 IN THE TREATMENT AND DIAGNOSIS OF CANCER</b>				
				
I hereby certify that the following correspondence:				
<div style="border: 1px solid black; padding: 10px; margin: 10px auto; width: 80%;">Reply to Restriction Requirement</div> <p><i>(Identify type of correspondence)</i></p>				
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on				
<div style="display: flex; justify-content: space-between;"><div style="text-align: center;"><u>January 13, 2005</u> <i>(Date)</i></div><div style="text-align: center;"><u>Jane Massey Licata</u> <i>(Typed or Printed Name of Person Mailing Correspondence)</i></div></div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div></div><div style="text-align: center;"> <i>(Signature of Person Mailing Correspondence)</i></div></div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div></div><div style="text-align: center;"><u>EV540196370US</u> <i>("Express Mail" Mailing Label Number)</i></div></div>				
Note: Each paper must have its own certificate of mailing.				



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 270/070 (UMD-0070)  
Inventors: Langenfeld, John  
Serial No.: 10/044,716  
Filing Date: January 11, 2002  
Examiner: Rawlings, Stephen L.  
Customer No.: 46046  
Group Art Unit: 1642  
Confirmation No.: 1276  
Title: Bone Morphogenetic Protein-2 in the  
Treatment and Diagnosis of Cancer

"Express Mail" Label No. EV540196370US  
Date of Deposit January 13, 2005

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Mail Stop Non-Fee Amendment, Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

REPLY TO OFFICE COMMUNICATION

This is a reply to the Office Communication mailed December 13, 2004 setting a one (1) month period for response. Please enter the following remarks into the record.

Amendment to the Claims are reflected in the listing of claims which begin on page 3 of this paper.

Attorney Docket No.: 270/070 (UMD-0070)  
Inventors: Langenfeld, John  
Serial No.: 10/044,716  
Filing Date: January 11, 2002  
Page 2

**Remarks** being on page 13 of this paper.